iiinova — where your digital self keeps evolving

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 04/09/2026

On 30 September, the GNA NOW consortium, supported by the COMBINE project, is bringing two presentations from its recent GAMRIC 2026 symposium to a wider audience. If you couldn't make it to the conference, this is your chance to catch up. 📅 30 September 2026 | 15:30–17:00 CEST | Online Link 👇

102

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 04/09/2026

102

Reposted by IMI AMR ACCELERATOR

European Vaccine Initiative e.V. @europevaccine.bsky.social · 29/06/2026

Today, 8 PDPs launched a call for sustained EU funding for EDCTP — supporting 20+ years of Europe–Africa clinical research, capacity strengthening, and innovation for global health security. Learn more: www.euvaccine.eu/post/evi-joi...

141

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 02/07/2026

Last week, the RespiriTB consortium shared some of its most significant results: 🔬 First-in-human PK & safety data for bedaquiline long-acting injectable 🧬 CryoEM structures of cytochrome bc₁:aa₃ inhibitors 💊 MenG inhibitors resensitising bedaquiline-resistant M. tuberculosis 1/2

131

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 21/05/2026

🎙️ Meet our speakers on June 23: Dr. Clara Aguilar Pérez, Senior Principal Scientist at Johnson & Johnson, has specialized in preclinical in vivo models, clinical microbiology, and cross-functional collaborations supporting drug development and regulatory interactions. #AMR #webinar

221

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 20/05/2026

🎙️ Meet our speakers: Vivian Cox will speak at the RespiriTB Stakeholder Webinar on 23 June and present interim results from J&J's ongoing Phase 1 study of a bedaquiline long-acting injectable that could transform TB preventive treatment by replacing months of daily pills with a single injection.

101

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 05/05/2026

𝗗𝗲𝗰𝗼𝗱𝗶𝗻𝗴 𝗜𝗺𝗺𝘂𝗻𝗲 𝗗𝘆𝘀𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 In this study published by researchers from the RespiriNTM project explored how immune signaling pathways and cellular responses become dysregulated in disease, shaping inflammation and clinical outcomes. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

121

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 29/04/2026

𝗔𝗳𝘁𝗲𝗿 𝘆𝗲𝗮𝗿𝘀 𝗼𝗳 𝘄𝗼𝗿𝗸, 𝘁𝗵𝗲 𝗥𝗲𝘀𝗽𝗶𝗿𝗶𝗧𝗕 𝗰𝗼𝗻𝘀𝗼𝗿𝘁𝗶𝘂𝗺 𝗶𝘀 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝘄𝗵𝗮𝘁 𝗶𝘁 𝗳𝗼𝘂𝗻𝗱 — 𝗮𝗻𝗱 𝘁𝗼 𝘀𝘁𝗮𝗿𝘁 𝗮 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗶𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗳𝘂𝘁𝘂𝗿𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝗻 𝗔𝗠𝗥. On 23 June 2026, 3:30-5 pm, we're hosting a free stakeholder webinar open to everyone. Register now: forms.cloud.microsoft/e/dMq37JFx9z

022

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 29/04/2026

022

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 15/04/2026

✨ We're excited to introduce Linda De Vooght — postdoctoral researcher at the RespiriTB project and the newest face in our AMR Accelerator researcher spotlight series! "Antibiotics should not be taken for granted. People are already dying from infections that are difficult or impossible to treat."

110

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 15/04/2026

010

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 02/04/2026

📢 𝙅𝙪𝙨𝙩 𝙥𝙪𝙗𝙡𝙞𝙨𝙝𝙚𝙙! 𝗧𝗼𝘄𝗮𝗿𝗱𝘀 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗩𝗮𝗰𝗰𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗖. 𝗱𝗶𝗳𝗳𝗶𝗰𝗶𝗹𝗲 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 Today we highlight a study by researchers from the COMBINE project published in Scientific Reports analysing data from over 1,000 participants across Phase II and III clinical trials of 𝘊𝘭𝘰𝘴𝘵𝘳𝘪𝘥𝘪𝘰𝘪𝘥𝘦𝘴 𝘥𝘪𝘧𝘧𝘪𝘤𝘪𝘭𝘦 vaccines.

000

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 24/03/2026

𝗥𝗲𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗧𝗕 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗶𝗻 𝗛𝗶𝗴𝗵-𝗕𝘂𝗿𝗱𝗲𝗻 𝗦𝗲𝘁𝘁𝗶𝗻𝗴𝘀 Today we highlight a study by researchers of UNITE4TB published in Breathe examining the implementation of molecular diagnostic tools for tuberculosis in resource-limited, high-burden countries. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

211

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 18/03/2026

✨ Meet Maya Rima, early-career researcher in the RespiriNTM project and the latest voice in our AMR Accelerator researcher spotlight series! We are grateful to Maya for sharing her journey, her insights, and her passion. Find the the link to her interview in the first comment 👇

111

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 10/03/2026

Our annual Cross Project Meeting of the IMI AMR Accelerator took place on 5 March at BioVersys AG in Basel — and it was a very productive one! Representatives from all projects came together to present progress & discuss the plans ahead. It was great to see the breadth of work across the portfolio.

000

Reposted by IMI AMR ACCELERATOR

Ecraid @ecraid.bsky.social · 06/03/2026

🫱🏼‍🫲🏻 We're proud to present the #PrIMAVeRaProject and our #perpetualobervationalstudies at the 7th @amr-accelerator.bsky.social Cross-Project Meeting held in Basel yesterday. We look forward to seeing everyone again at the PrIMAVeRa stakeholder meeting at #ESCMID2026! @elskesieswerda.bsky.social

123

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 04/03/2026

We’re live at the AMR Conference in Basel — come meet us today! 📍 Machine Learning for Gram-negative Permeability (Frederik Deroose) 📍 Improving Translational Pneumonia Models (Carina Vingsbo-Lundberg) 💬 Stop by the posters, say hello, and explore collaboration opportunities.

131

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 04/03/2026

📢 Call for Data: Help Advance Antibiotic Discovery Against Gram-Negative Bacteria! The AMR Accelerator Scientific Interest Group on Machine Learning is building a predictive model for membrane permeability in Gram-negative bacteria — and we need your support. Link to the survey in first comment 👇

222

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 03/03/2026

Meet us at the AMR Conference in Basel today and tomorrow! 🧠 Researchers from different projects of the accelerator are presenting posters on Machine Learning for Gram-negative permeability 🧪 Advancing TB drug development with HFS-TB 🫁 The COMBINE Pneumonia Model Will you be there? Get connected!

132

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 25/02/2026

𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗧𝗕 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 Today we highlight a study published by ERA4TB. It contributes to a growing pipeline of compounds designed to tackle drug-resistant TB through novel mechanisms and strategies. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

211

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 17/02/2026

𝗥𝗲𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝗧𝗕 𝗣𝗵𝘆𝘀𝗶𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 A study published by members of our project ERA4TB uncovers how 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 forms tightly biofilm-like cords that dramatically alter its interaction with the immune system. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇 #amr #tuberculosis #antibiotics

112

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 17/02/2026

112

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 25/11/2025

Hear from Marie Attwood (@reepkpd333.bsky.social) in an exclusive interview about her work in using 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 models in AMR research as a GNA NOW PK/PD expert. She offers insights into: 🔬 Decade of progression 🧫 Hollow-fibre modelling 🦠 AI-driven discovery 🔗 bit.ly/4plTnqW

032

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 27/11/2025

We are excited to share the latest work under RespiriTB, published in Nature Communications! The study explores how targeting the M. tuberculosis cytochrome bc1 complex could unlock new treatment options for both DS-TB & MDR-TB. 👉 go.nature.com/48cWgEV

032

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 25/12/2025

How can we speed up TB clinical trials efficiently? Our latest work led by global TB experts, under UNITE4TB defines the ideal biomarker assays to reliably track treatment response, therefore helping trials be faster, smarter and more effective. 👉 Read at: bit.ly/4iVmPAu

042

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 12/02/2026

𝗨𝗻𝗺𝗮𝘀𝗸𝗶𝗻𝗴 𝗛𝗼𝘀𝘁–𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗕 Today we showcase a study by our project ERA4TB revealing a previously underappreciated mechanism by which 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 aggregates kill macrophages without being taken up by them. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

032

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 12/02/2026

032

Reposted by IMI AMR ACCELERATOR

Innovative Health Initiative @ihieurope.bsky.social · 11/02/2026

♀️ Today is the #InternationalDayofWomenandGirlsinScience! 🧠 Meet Ariane Bollack, a former PhD student from the AMYPAD project who's now working in industry. We asked her how the PPP shaped her career & what advice she has for young researchers 👉 link.europa.eu/K6GPPp #WomenInScience #WomenInSTEM

Today is the International Day of Women and Girls in Science, and we're shining the spotlight on Ariane Bollack, who took part in the AMYPAD project as a PhD student. We asked her how taking part in the PPP shaped her career.

092

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 11/12/2025

In this latest study under @era4tb.bsky.social, researchers adopted physiologically‑based pharmacokinetic (PBPK) modelling and used a detailed computational model to project what those concentrations likely are in human lungs (both healthy and TB-infected). 👉 Read at: bit.ly/3KA2RQx

023

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 16/12/2025

Hear from Pedro Quintela in an interview about his work in GNA NOW advancing 𝘪𝘯 𝘷𝘪𝘷𝘰 proof-of-concept models for AMR research. He shares insights into: 🦠 Broader pathogen coverage 🤝 Interdisciplinary collaboration 💡 Championing the promise of each experiment bit.ly/49Hdtr1

012

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 05/02/2026

𝗧𝗵𝗲 𝗖𝗢𝗠𝗕𝗜𝗡𝗘 𝗣𝗻𝗲𝘂𝗺𝗼𝗻𝗶𝗮 𝗠𝗼𝗱𝗲𝗹: 𝗡𝗲𝘄 𝘁𝗼𝗼𝗹𝘀 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗱𝗿𝘂𝗴-𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝘁 𝗽𝗻𝗲𝘂𝗺𝗼𝗻𝗶𝗮 𝗡𝗼𝘄 𝗽𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗦𝗽𝗲𝗰𝘁𝗿𝘂𝗺, this framework is openly available to academia, CROs, and industry. A real enabler for accelerating antibiotics against WHO-listed critical pathogens. #AMR

COMBINE Pneumonia Model by AMR Accelerator Project

210

Reposted by IMI AMR ACCELERATOR

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 02/12/2025

🚨 The AMR Accelerator needs your help! Our Machine Learning group seeks datasets to build a Gram-negative permeability prediction model. 𝗜𝗳 𝘆𝗼𝘂 𝗵𝗮𝘃𝗲 𝘀𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗱𝗮𝘁𝗮𝘀𝗲𝘁𝘀, 𝗽𝗹𝗲𝗮𝘀𝗲 𝘃𝗶𝘀𝗶𝘁: bit.ly/4piUvMw Fill out a form and we will contact you!

033

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 03/02/2026

𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗧𝗕 𝗥𝗲𝗴𝗶𝗺𝗲𝗻𝘀 Today we highlight a study from the RespiriTB project, published in Nature Communications investigating cytochrome bc₁ inhibitors as novel partners in tuberculosis combination therapy. Find out 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

242

Reposted by IMI AMR ACCELERATOR

Innovative Health Initiative @ihieurope.bsky.social · 03/02/2026

🏭 IMI & IHI projects are helping to make the manufacture of medical products in Europe better, faster & cheaper, boosting #EUCompetitiveness & strengthening #HealthResilience - find out how:👉 lnkd.in/eFczWHw2 #IHITransformingHealth #HealthUnion #MedicinesManufacture #MedicalDevices #MedTech

042

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 25/12/2025

042

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 23/12/2025

✨ With 2025 coming to an end, we at the AMR Accelerator are taking a moment to thank all our projects, partners, researchers and supporters. Wishing everyone of you a warm holiday season and see you again in 2026, where our story continues....

010

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 18/12/2025

In our latest study under RespiriTB, researchers developed a fast “screening factory” to test hundreds of compounds against a key TB enzyme, mycothione reductase, which is crucial bacterial survival mechanism. 👉 𝗥𝗲𝗮𝗱 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: bit.ly/4orDHl4

011

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 16/12/2025

012

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 11/12/2025

023

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 09/12/2025

Webinar recording is now live! Previous month, a joint effort from COMBINE, ERA4TB AND GNA NOW (Lygature) under AMR Accelerator resulted in an exciting webinar on hollow fiber assays in antimicrobial drug development. Check out the key takeaways & watch the recording here bit.ly/4psEqDU

020

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 04/12/2025

Our latest review under PrIMAVeRa maps out the evidence on bloodstream infections caused by six high-priority resistant pathogens. Finding? Lots of data on resistance percentage Little data on how many infections actually occur 👉 Read complete paper at: bit.ly/4rpZ1Kx

011

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 02/12/2025

033

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 27/11/2025

032

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 25/11/2025

032

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 20/11/2025

Is this research unit ready to safely run a first-in-human trial? ERA4TB researchers designed a "feasibility form" that sets minimal criteria a Clinical Trial Unit must meet, jointly agreed by academia and industry, to follow key standards. 👉 Read complete paper at: bit.ly/486LwGK

001

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 18/11/2025

As we approach the end of the year, the AMR Accelerator is only gaining momentum. With the #WAAW2025 underway, this month’s newsletter is a gentle nudge to our community, offering a clear snapshot of what has been happening across our projects and what is coming next. 👉 bit.ly/4o2iQEQ

001

Reposted by IMI AMR ACCELERATOR

Innovative Health Initiative @ihieurope.bsky.social · 18/11/2025

📢 Thanks to the efforts of projects funded by IMI and @globalhealthedctp3.bsky.social, we're a step closer to getting a new weapon in the fight against #tuberculosis 💊 Get the full story & meet the people behind this work at our webinar on 9 Dec 👉 link.europa.eu/WbjvxK @amr-accelerator.bsky.social

Impact on TB: Partnerships joining forces to combat TB
09.12.2025
14:00 – 15:30 Brussels time
Online event
Learn how the IMI2 and EDCTP2 partnerships led to the development of a new way for treating TB, which could help to fight multi-drug resistant TB

042

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 18/11/2025

#WAAW 2025 calls on all of us to act, because #AMR is no longer tomorrow’s problem. This week, #AMR Accelerator highlights researchers and leaders turning ideas into impact, protecting today and securing our future. 👉 Read the full feature here: bit.ly/3K7ECcb ‎

011

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 13/11/2025

Our latest Primavera study shows Klebsiella pneumoniae, E. coli and MRSA cause the most preventable harm in surgical, cancer & transplant patients. The impact? Vaccines or mAbs could cut infections, hospital stays and antibiotic use. 👉 Read the full paper here: bit.ly/3JStwYn

021

IMI AMR ACCELERATOR @amr-accelerator.bsky.social · 11/11/2025

𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗜𝘀 𝗡𝗼𝘄 𝗢𝗽𝗲𝗻!! Reserve your spot today for the upcoming COMBINE-GNA NOW and webinar on i𝘯 𝘷𝘪𝘵𝘳𝘰 standardisation in antimicrobial drug development. Register now to secure your spot: bit.ly/4nQvPsR

011